COMMUNIQUÉS West-GlobeNewswire

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
18/03/2024
BRISBANE, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating [...]
Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
18/03/2024
Initiated limited U.S. commercial launch of the Pure-Vu ® EVS Gastro and Gen 4 Colon system, including successful UGI procedures at several leading hospital systems The Company is engaged in the process to seek [...]
Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin
18/03/2024
The study, published in the journal Molecular Psychiatry , suggests that nature-derived psilocybin may be demonstrably more therapeutic than its synthetic analog Benefits are thought to include a more potent and [...]
Madrigal Pharmaceuticals Announces Proposed Public Offering
18/03/2024
CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today [...]
Carina Biotech to Present Three Poster Presentations at AACR Annual Meeting 2024
18/03/2024
ADELAIDE, Australia, March 18, 2024 (GLOBE NEWSWIRE) -- Carina Biotech Limited (Carina), a clinical stage cell therapy immuno-oncology company, today announced three poster presentations from studies of its LGR5- [...]
Augmedix Delivers 45% Revenue Growth and Expanded Gross Margins for Fourth Quarter of 2023
18/03/2024
SAN FRANCISCO, March 18, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three and 12 months ended December 31 [...]
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer
18/03/2024
Phase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt (PC14586) i n heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation featured in a late- [...]
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
18/03/2024
LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo. Statistical significance was also [...]
Inventiva annonce les résultats positifs de l’essai clinique de Phase II, preuve de concept, LEGEND, combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de diabète de type 2
18/03/2024
LEGEND a atteint son critère principal d’efficacité en réduisant de manière significative le taux d’hémoglobine HbA1c dans les groupes recevant lanifibranor seul ou en combinaison avec empagliflozine, par rapport au [...]
Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.
18/03/2024
One-time treatment with Lenmeldy has shown the potential to restore enzymatic function to stop or slow disease progression, with up to 12 years of follow-up (median 6.76 years) TOKYO and LONDON and BOSTON, March 18, [...]
Carmell to Host Investor Webinar, “Unveiling the Secretome: On the Eve of Product Launch” Featuring Key Opinion Leaders in the Medical Aesthetics Field
18/03/2024
Register for Webinar to be held on March 20, 2024 at 3:00 pm EDT PITTSBURGH, March 18, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell” or [...]
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
18/03/2024
Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its [...]
Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023
18/03/2024
Strong Start to 2024 with Unaudited Revenue Climbing 229.1% in First Two Months of 2024 YoY Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR) , the global leader in blood volume [...]
TaiMed Biologics and AcedrA BioPharmaceuticals Partner to Commercialize Trogarzo® (Ibalizumab-uiyk) in the Middle East and North Africa Region
18/03/2024
TAIPEI, Taiwan and RIYADH, Saudi Arabia, March 18, 2024 (GLOBE NEWSWIRE) -- TaiMed Biologics (“TaiMed”), a publicly held Taiwanese biotechnology company, signed an Exclusive License and Distribution Agreement with [...]
Progyny, Inc. to Present at KeyBanc Life Sciences & MedTech Investor Forum
18/03/2024
NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits solution, today announced that Pete Anevski, Progyny’s Chief Executive [...]
RS BioTherapeutics Selected for Presentation at American Thoracic Society’s 2024 Respiratory Innovation Summit
18/03/2024
CUMBERLAND, Md., March 18, 2024 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation, is [...]
Novonesis will host a conference call regarding 2024 outlook and 2023 pro forma financials on March 21
18/03/2024
Novonesis will host a conference call regarding 2024 outlook and 2023 pro forma financials on March 21 at 9.00am CET. To join the live webcast, please click here . To register and receive access details for the [...]
Novo Nordisk A/S - share repurchase programme
18/03/2024
Bagsværd, Denmark, 18 March 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
Medigene AG to report full year 2023 financial results on March 28, 2024
18/03/2024
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will report financial results [...]

Pages